Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CSF3R | Q99062 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4368371 | 0.90 | PARP10 (0.46) | PLA2G2APARP10PRSS1F2PRSS2 | |
| SCHEMBL25724576 | 0.86 | PARP10 (0.46) | PLA2G2APARP10PRSS1F2PRSS2 | |
| Hexanoate SCHEMBL29036122 | 0.84 | PLA2G2A (0.55) | PLA2G2ATSHRCSF3R | |
| SCHEMBL17414620 | 0.83 | PLA2G2A (0.62) | PLA2G2APARP10TSHR | |
| SCHEMBL9448432 | 0.82 | PRSS1 (0.58) | PARP10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL9448533 | 0.81 | SIRT2 (0.48) | — | |
| SCHEMBL16447478 | 0.81 | TAAR1 (0.44) | PLA2G2A | |
| SCHEMBL6836738 | 0.81 | PLA2G2A (0.54) | PLA2G2APARP10PRSS1F2PRSS2 | |
| SCHEMBL27987025 | 0.81 | PARP10 (0.68) | PARP10PRSS1F2ST14PARP1 | |
| SCHEMBL5086980 | 0.80 | PLA2G2A (0.73) | PLA2G2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080213187-A1 | NOVEL CASCADE POLYMER COMPLEXES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | EPIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | claimed |
| US-20080213187-A1 | NOVEL CASCADE POLYMER COMPLEXES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | EPIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213187-A1 | NOVEL CASCADE POLYMER COMPLEXES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PGF, F13A1, F11 | PLA2G2A 4733/4885PARP10 120/4885PRSS1 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.